10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
With a market cap hovering near $60 billion, Argenx SE (NASDAQ: ARGX) is no longer a new kid on the block in the biopharmaceutical world. However, the drugmaker still has a long way to go before becoming one of the largest healthcare companies . Quite a few people on Wall Street believe that Argenx will make some headway on that goal in the near future, though. While the biotech stock was priced at roughly $919 as of the market close on Friday, Oct. 2, 2026, 10 analysts predict that it's headed to at least $1,200 over the next 12 months. Image source: Getty Images. Continue reading